Pulsed field ablation (PFA) seems to have seized the moment in the field of cardiac electrophysiology, given its seemingly superior performance over other ablation modalities as a treatment for atrial fibrillation (AF). New data from three studies were presented at this year’s annual meeting of the Heart Rhythm Society that further confirm the value of PFA as a treatment for both persistent and paroxysmal AF with data sets that seem to confirm that PFA is poised to sweep aside the current standards for ablation, potentially overturning a treatment paradigm that took decades to establish.
Recent developments may seem to have rendered artificial intelligence (AI) little more than the latest internet sensation, but a presentation at this year’s annual meeting of the Heart Rhythm Society confirms yet again that AI is much more than just a trend. A new AI algorithm paired with a single-lead electrocardiogram accurately predicted the onset of ventricular tachycardia in 88% of patients in an outcome that could enable cardiologists to thwart thousands of sudden cardiac death (SCD) events each year, potentially ushering in a new age of cardiac care across the globe.
Boston Scientific Corp. reported positive results for its Emblem subcutaneous implantable defibrillator (S-ICD) system and next-generation Watchman Flx left atrial appendage closure (LAAC) device at the Heart Rhythm Society scientific sessions, which were online only this year due to the COVID-19 pandemic.